Anxiolytic agents with reduced sedative and ataxic effects

Details Anxiolytic agents with reduced sedative and ataxic effects Anxiolytic agents with reduced sedative and ataxic effects

2006-10-10

2006-10-10

Kifle, Bruck (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

Reexamination Certificate

active

07119196

ABSTRACT:
Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

REFERENCES:
patent: 2893992 (1959-07-01), Sternbach
patent: 4280957 (1981-07-01), Walser et al.
patent: 4401597 (1983-08-01), Walser et al.
patent: 4959361 (1990-09-01), Walser
patent: 0 320 992 (1989-06-01), None
patent: WO 02/083652 (2002-10-01), None
Camille G. Wermuth, “Molecular Variations Based on Isosteric Replacements,” “The Practice of Medicinal Chemistry,” 1996, pp. 203-237, Academic Press Limited.
Qi Huang, et al., “Benzo-fused Benzodiazepines Employed as Topological Probes for the Study of Benzodiazepine Receptor Subtypes,” “Medicinal Chemistry Research,” 1996, pp. 384-391, Birkhauser Boston.
Ruiyan Liu, et al., “Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzodiazepines: High-Affinity, Selective Probes for a5-Containing GABAa Receptors,” “J. Med. Chem.,” 1996, pp. 1928-1934.
Armin Walser, et al., “Triazolobenzo- and Triazolothienodiazepines as Potent Antagonists of Platelet Activating Factor,” “Journal of Medicinal Chemistry,” 1991, pp. 1209-1221, vol. 34, No. 3, American Chemistry Society.
Qi Huang, “Part One: A Chemical and Computer Assisted Approach to Pharmacophore/Receptor Models for GABAa/BZ Receptor Subtypes; Part Two: Predictive Models for GABAa/BZR Subtypes Via Comparative Molecular Field Analysis,” DISSERTATION, UW-Milwaukee, 1998, pp. 1-296.
Shu Yu, et al., “Studies in the Search for a5 Subtype Selective Agonists for GABAa/BzR Sites,” “Medicinal Chemistry Research,” 1999, pp. 71-88, Birkhauser Boston.
Qi Huang, et al., “Pharmacophore Receptor Models for GABAa/BzR Subtypes (a1B3y2, a5B3y2, and a6B3y2) via a Comprehensive Ligand Mapping Approach,” “J. Med. Chem.,” 2000, pp. 71-95, American Chemical Society.
Xiaohui He, et al., “Pharmacophore/Receptor Models for GABAa/BzR a2B3y2, a3B3y2 and a4B3y2 Recombinant Subtypes. Induced Volume Analysis and Comparison to a1B3y2, a5B3y2 and a6B3y2 Subtypes,” “Drug Design and Discovery,” 2000, pp. 131-171, vol. 17, Overseas Publishers Association.
Xiaohui He, “Studies of Molecular Phamracophore/Receptor Models for GABAa/BzR Subtypes: Chemical and Computer Assisted Approach in Search of Selective Ligands for GABAa/BzR Subtypes,” DISSERTATION, UW-Milwaukee, 2000, pp. 1-300.
Le Solleu, et al., “Determination of a PAF Antagonist Pharmacophore Using Combined Molecular Electrostatic Potential and Molecular Lipophilicity Potential,” “Drug Design and Discovery,” 1994, pp. 149-167, vol. 12, Harwood Academic Publishers GmbH.
Yu, et al., “Studies in Search of alpha2 Selective Ligands for GABAa/BzR Receptor Subtypes. Part I. Evidence for the Conservation of Pharmacophoric Desciptors for DS Subtypes”, “Med. Chem. Res.,” 1999, pp. 186-202, vol. 9, No. 3, Birkhauser, Boston.
Bundgaard, H., “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities,” pp. 1-92 in Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., Amsterdam 1985.
Chambon, J.P., et al., Ethyl loflazepate: a prodrug from the benzodiazepine series designed to dissociate anxiolytic and sedative activities. Arzneimittelforschung. 1985;35(10):1573-7.
Cho, M.J., et al., Sequentially labile water-soluble prodrugs of alprazolam. J Med Chem. Aug. 1986; 29(8):1346-50.
Han, K.-Y., & Amidon, G.L., Targeted prodrug design to optimize drug delivery, AAPS Pharmsci. 2000; 2(1): 1-11, article 6, http://www.pharmsci.org/.
Mussini, E., et al., Hydroxylation of three benzodiazepines in vitro. J. Pharm Sci. Oct. 1977;66(10):1482-3.
Simon-Trompler, E., et al., Lorazepam and oxazepam esters. Hydrophobicity, hydrolysis rates and brain appearance. Arzneimittelforschung. 1982;32(2):102-5.
Tegyey, Z., et al., Comparison of dihydrodiazepam enantiomers: metabolism, serum binding and brain receptor binding. Experientia. Sep. 15, 1980;36(9):1031-2.

Affiliated with

Also associated with

Rating

Anxiolytic agents with reduced sedative and ataxic effects does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anxiolytic agents with reduced sedative and ataxic effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anxiolytic agents with reduced sedative and ataxic effects will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3699282